145 related articles for article (PubMed ID: 29153411)
1. How do we critically use long-acting muscarinic receptor antagonists and beta-adrenergic receptor agonists monotherapy, or these combination therapies depending on the situation in Japanese patients with COPD?
Kawayama T; Sasaki J
Respir Investig; 2017 Nov; 55(6):323-325. PubMed ID: 29153411
[No Abstract] [Full Text] [Related]
2. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the rapid effects of single inhalations of formoterol and tiotropium bromide on respiratory function and COPD symptoms in a randomized crossover study.
Ohbayashi H
Respir Investig; 2017 Nov; 55(6):348-356. PubMed ID: 29153415
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
5. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
8. COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.
Barrecheguren M; Miravitlles M
Chest; 2018 Oct; 154(4):749-751. PubMed ID: 30290926
[No Abstract] [Full Text] [Related]
9. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
Fujimoto K; Yamazaki H; Ura M; Kitaguchi Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3195-3201. PubMed ID: 29138547
[TBL] [Abstract][Full Text] [Related]
10. Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population.
Tsai MJ; Chen CY; Huang YB; Chao HC; Yang CJ; Lin PC; Tsai YH
Medicine (Baltimore); 2015 Dec; 94(51):e2306. PubMed ID: 26705214
[TBL] [Abstract][Full Text] [Related]
11. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
12. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK; Yoshisue H; Lad R
Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
[TBL] [Abstract][Full Text] [Related]
13. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
14. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
15. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
16. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
Med Lett Drugs Ther; 2016 Oct; 58(1505):130-132. PubMed ID: 27701364
[No Abstract] [Full Text] [Related]
17. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
Nagar S; Patel J; Stanford RH
Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
[TBL] [Abstract][Full Text] [Related]
19. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
Cazzola M; Molimard M
Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]